Skip to main content
. 2003 Oct 15;23(28):9374–9384. doi: 10.1523/JNEUROSCI.23-28-09374.2003

Figure 4.

Figure 4.

The CB1 antagonist SR141716A, infused locally in the hippocampus, attenuates the inhibitory but not the stimulatory effects of WIN55,212-2 on ACh efflux in this region. Intrahippocampal infusion of SR141716A [0.1 mm through the microdialysis probe for 30 min (filled bar) and 15 min before and 15 min after WIN55,212-2 injection (arrow)] did not attenuate the stimulatory effects of WIN55,212-2 (0.5 mg/kg) (a) (F(10,100) = 1.15; NS; three-way ANOVA) but reversed the inhibitory effects of WIN55,212-2 (5 mg/kg) (b) (F (10,120) = 2.09; p < 0.05; three-way ANOVA) on ACh efflux in the hippocampus. Data (expressed as fold over baseline established before any treatment) represent mean ± SEM of n = 4-6 animals per group. *p < 0.05, **p < 0.01, and ***p < 0.001 for animals infused with SR141716A and treated with WIN55,212-2 versus animals treated with WIN55,212-2 only, at each time point.